Compliance and health status
Compliance was 97.1 ± 0.6% in period 1 and 96.4 ± 0.6% in period 2, without significant differences between periods (This clinical trial started after the third wave of COVID-19 in Spain, March 2021, and we recorded that due to possible infection/contagion several volunteers did not take the capsule on sporadic days. Other health issues were negligible and did not affect the trial performance.